CoChat

An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy

Open access
Lach-Trifilieff, Estelle, Minetti, Giulia C., Sheppard, KellyAnn, Ibebunjo, Chikwendu, Feige, Jerome N., Hartmann, Steffen, Brachat, Sophie, Rivet, Helene, Koelbing, Claudia, Morvan, Frederic, Hatakeyama, Shinji, Glass, David J. · 2014 · Molecular and Cellular Biology

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Abstract

The myostatin/activin type II receptor (ActRII) pathway has been identified to be critical in regulating skeletal muscle size. Several other ligands, including GDF11 and the activins, signal through this pathway, suggesting that the ActRII receptors are major regulatory nodes in the regulation of muscle mass. We have developed a novel, human anti-ActRII antibody (bimagrumab, or BYM338) to prevent binding of ligands to the receptors and thus inhibit downstream signaling. BYM338 enhances differentiation of primary human skeletal myoblasts and counteracts the inhibition of differentiation induced by myostatin or activin A. BYM338 prevents myostatin- or activin A-induced atrophy through inhibition of Smad2/3 phosphorylation, thus sparing the myosin heavy chain from degradation. BYM338 dramatically increases skeletal muscle mass in mice, beyond sole inhibition of myostatin, detected by comparing the antibody with a myostatin inhibitor. A mouse version of the antibody induces enhanced muscle hypertrophy in myostatin mutant mice, further confirming a beneficial effect on muscle growth beyond myostatin inhibition alone through blockade of ActRII ligands. BYM338 protects muscles from glucocorticoid-induced atrophy and weakness via prevention of muscle and tetanic force losses. These data highlight the compelling therapeutic potential of BYM338 for the treatment of skeletal muscle atrophy and weakness in multiple settings.

Overview

Integrity signals

Registry

Crossref · 10.1128/mcb.01307-13

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Research works printed but not linked: 1

  1. Glass D, 2010, Curr. Top. Microbiol. Immunol., 346, 267

Cited by

See all 306

Metadata

Authors
Lach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., Hatakeyama, S., & Glass, D. J.
Affiliations
  • MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, Basel, Switzerland
  • Novartis (Switzerland) (CH)
  • Development and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA
  • Novartis Institutes for BioMedical Research (CH)
Venue
Molecular and Cellular Biology
Published
2014-02-01
Volume
34
Issue
4
Pages
606-618
ISSN
  • 0270-7306 (ISSN-L)
  • 1098-5549
OpenAlex
W2102107385
Cited by
306
References
58
Citations by year
2026: 22 · 2025: 16 · 2024: 19 · 2023: 21 · 2022: 20 · 2021: 37 · 2020: 29 · 2019: 28 · 2018: 25 · 2017: 18 · 2016: 29 · 2015: 21 · 2014: 19
FWCI
10.44
Type
journal article
Language
en
Open access
Licence
journals.asm.org/non-commercial-tdm-license (tdm)
Locations
  • Molecular and Cellular Biology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Novartis
  • MorphoSys
  • Novartis Pharma
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
Keywords
activin type II receptor, bimagrumab, myostatin, skeletal muscle hypertrophy, muscle atrophy, Smad2/3 phosphorylation, skeletal myoblast differentiation, activin A, GDF11, muscle weakness, myosin heavy chain degradation, muscle mass regulation
MeSH terms
Animals, Antibodies, Monoclonal, Atrophy, Cell Differentiation, Humans, Hypertrophy, Signal Transduction, Muscle, Skeletal, Antibodies, Blocking, Activins, Activin Receptors, Type II, Myoblasts, Skeletal, Mice, Smad2 Protein, Smad3 Protein, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.